We are dedicated to improving the lives of those suffering from neurodegenerative diseases. We solve problems with rigorous science and innovative therapies. We have assembled a team with deep scientific, clinical, commercial, and leadership experience and expertise in medical technology and neurodegenerative diseases.
Science Officer, Co-Founder
Karl Kieburtz, MD, MPH
Former President and CEO at Apollo Light Systems where he led efforts to innovate, patent and deliver specialized light therapy devices for mood and sleep disorders to more than 300,000 patients (sold to Philips Respironics).
Suzanne Hendrix, PhD
Brad Wyman, PhD
VP Quality & Regulatory
C. Warren Olanow, MD
Ray Chaudhuri, MD
Rajeesh Pahwa, MD
Joohi Jimenez-Shahed, MD
Dan Claassen, MD, MS
Amy Amara, MD, PhD
George Brainard, PhD
The Cycle of Innovation, Clinical Research, and Improved Lives
For decades, our founders developed innovative specialized phototherapy devices for circadian-related neuropsychiatric disorders. They validated the new devices’ safety and efficacy in human clinical trials and delivered those innovations to and improved the lives of hundreds of
They have now applied their expertise to circadian dysregulation in neurodegenerative disease. Building on this, we have created a new platform technology and developed a safe and convenient product for Parkinson’s patients. PhotoPharmics is now validating this product in robust clinical research. After demonstrating safety and efficacy, these products will become widely available for people with Parkinson’s.
In addition to improving the lives of Parkinson’s patients, recent science and clinical evidence leads us to believe that specialized phototherapy can contribute to the treatment of other neurodegenerative diseases. PhotoPharmics is now applying what we’ve learned in Parkinson’s to other age-related neurodegenerative diseases. We will validate those products in clinical research, and if successful, deliver the solutions to individuals who suffer from these diseases.